INmune Bio Inc. (NASDAQ: INMB) Planning Phase II T
Post# of 33
(Total Views: 280)
Posted On: 08/07/2019 4:58:45 PM
INmune Bio Inc. (NASDAQ: INMB) Planning Phase II Trial of INB03 as Part of Combination Immunotherapy for Cancer Patients
- INmune Bio is currently attending the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit in Boston
- Co-founder and CEO Dr. RJ Tesi is presenting positive preliminary data on INB03, which is being developed as part of a combination immunotherapy to potentially reverse resistance to treatment
- The annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides unique opportunities to connect scientists with the latest discoveries in the field
An international mix of thought leaders and decision makers from the international immunotherapy and immuno-oncology community are gathering in Boston this week, with INmune Bio co-founder and CEO Dr. RJ Tesi slated to deliver several presentations. A news release outlining Tesi’s agenda at the five-day Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit highlights INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease (http://nnw.fm/1jH3I).
“We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” Tesi stated in a news release. “I am delighted to have the chance to present with some of the most prominent leaders in the immuno-oncology community.”
A fast-growing cancer patient population that is resistant to checkpoint inhibitors (“CPI”) was the focus of Tesi’s presentation on Monday, August 5, under the title ‘Targeting Soluble TNF to Improve Efficacy of Combination Immunotherapy’. During his presentation, Tesi reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients (http://nnw.fm/Wu2Ao).
“The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,” continued Tesi, who is also INmune Bio’s chief medical officer. “All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.”
The Phase I trial is an open-label, dose-escalation trial in patients with advanced solid tumors. Patients received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by leveraging a dominant-negative technology. Positive preliminary data from the first two cohorts were released. That data will be followed by a final report later this year as the company advances the program into a Phase II study.
Tesi is also speaking on ‘Next-Generation Immunotherapies’ and ‘Targeting ‘Protector’ Cells of the Innate Immune System’ during the summit. The Cambridge Healthcare Institute’s annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides a unique opportunity to network with decision-makers, build lasting collaborations and gain actionable solutions.
INmune Bio also recently attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan, where Tesi gave a talk titled ‘Combination Immunotherapy to Overcome Resistance to Cancer Treatments’. His presentation centered on monotherapy with checkpoint inhibitors (“CPI”) as an effective treatment option. The combination of CPI and other therapies may improve outcomes in patients who are unresponsive to monotherapy, an article explains (http://nnw.fm/9dBrv).
INmune Bio’s product pipeline targets three segments of concern: Alzheimer’s disease/dementia, which claims 5.5 million patients in the U.S.; cancer residual disease, which is expected to generate more than 1.7 million new cases yearly; and resistance to immunotherapy. INmune Bio is currently working on three product platforms: INKmune and INB03, which modify a patient’s innate immune response to cancer; and XPro1595, which targets inflammation linked to Alzheimer’s disease.
For more information, visit the company’s website at www.INmuneBio.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- INmune Bio is currently attending the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit in Boston
- Co-founder and CEO Dr. RJ Tesi is presenting positive preliminary data on INB03, which is being developed as part of a combination immunotherapy to potentially reverse resistance to treatment
- The annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides unique opportunities to connect scientists with the latest discoveries in the field
An international mix of thought leaders and decision makers from the international immunotherapy and immuno-oncology community are gathering in Boston this week, with INmune Bio co-founder and CEO Dr. RJ Tesi slated to deliver several presentations. A news release outlining Tesi’s agenda at the five-day Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit highlights INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease (http://nnw.fm/1jH3I).
“We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” Tesi stated in a news release. “I am delighted to have the chance to present with some of the most prominent leaders in the immuno-oncology community.”
A fast-growing cancer patient population that is resistant to checkpoint inhibitors (“CPI”) was the focus of Tesi’s presentation on Monday, August 5, under the title ‘Targeting Soluble TNF to Improve Efficacy of Combination Immunotherapy’. During his presentation, Tesi reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients (http://nnw.fm/Wu2Ao).
“The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,” continued Tesi, who is also INmune Bio’s chief medical officer. “All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.”
The Phase I trial is an open-label, dose-escalation trial in patients with advanced solid tumors. Patients received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by leveraging a dominant-negative technology. Positive preliminary data from the first two cohorts were released. That data will be followed by a final report later this year as the company advances the program into a Phase II study.
Tesi is also speaking on ‘Next-Generation Immunotherapies’ and ‘Targeting ‘Protector’ Cells of the Innate Immune System’ during the summit. The Cambridge Healthcare Institute’s annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides a unique opportunity to network with decision-makers, build lasting collaborations and gain actionable solutions.
INmune Bio also recently attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan, where Tesi gave a talk titled ‘Combination Immunotherapy to Overcome Resistance to Cancer Treatments’. His presentation centered on monotherapy with checkpoint inhibitors (“CPI”) as an effective treatment option. The combination of CPI and other therapies may improve outcomes in patients who are unresponsive to monotherapy, an article explains (http://nnw.fm/9dBrv).
INmune Bio’s product pipeline targets three segments of concern: Alzheimer’s disease/dementia, which claims 5.5 million patients in the U.S.; cancer residual disease, which is expected to generate more than 1.7 million new cases yearly; and resistance to immunotherapy. INmune Bio is currently working on three product platforms: INKmune and INB03, which modify a patient’s innate immune response to cancer; and XPro1595, which targets inflammation linked to Alzheimer’s disease.
For more information, visit the company’s website at www.INmuneBio.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)